Latest Strategy News

Rapid Critical Metals has initiated a 2,000m diamond drilling campaign at its Webbs Silver Project in NSW, aiming to upgrade its resource to 2025 JORC standards and explore new high-potential silver targets.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

betr Entertainment Limited posts a 140% turnover increase to $1.42 billion and achieves a positive EBITDA of $7.2 million in FY25, driven by strategic mergers and market exits. The company ups its takeover bid for PointsBet, signaling aggressive consolidation ambitions.

Catalina Resources is launching a Reverse Circulation drilling program at its Laverton Gold Project to explore extensions of promising gold zones along a key structural corridor in Western Australia.

Centuria Industrial REIT has expanded its exchangeable notes offering to $325 million, reflecting robust investor appetite, while simultaneously repurchasing nearly all its existing notes due 2028.

Resimac Group Ltd delivered a robust FY25 performance, marked by strong organic growth in home loans and asset finance, bolstered by the strategic acquisition of Westpac's $1.5 billion auto portfolio. The company raised dividends to 19 cents fully franked, reflecting confidence amid rising impairment expenses.

Godolphin Resources is raising $3.03 million through a placement and entitlement offer to fast-track exploration and development at its Lewis Ponds Project in NSW, following a significant resource upgrade.

betr Entertainment Limited marked a transformative FY25 with a successful merger, strategic acquisitions, and a sharp reduction in losses, setting the stage for a major takeover bid of PointsBet.

Australian Unity Office Fund reports a $35.6 million loss for FY25 as it advances asset disposals ahead of planned delisting, with the final property sale facing settlement uncertainty.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.